As one of the founders of the company, MYM Nutraceuticals (CSE:MYM) Executive Chairman Erick Factor has seen MYM transition from a production- and manufacturing-focused company towards being a global, fully integrated cannabis brand.
Since going public in 2014, the company has increased the number of its product lines and has entered into multiple jurisdictions around the world, making a point of building syndicates of doctors and other opportunities for educating communities on the cannabis plant.
In the interview below, Factor provides highlights on the company’s work as it moves towards being a global brand. He also outlines his views on the Canadian cannabis market and on how the North American country will become a leader in best practises for cannabis production once recreational legalization is deployed.
Below is a transcript of our interview with MYM Nutraceuticals Executive Chairman Erick Factor. It has been edited for clarity and brevity.
Investing News Network: Please give our investor audience an overview of MYM and its position as a global cannabis company.
MYM Nutraceuticals Executive Chairman Erick Factor: When MYM went public in 2014, the intention of the company was to be a fully integrated, seed-to-sale global brand. With that in mind, we have been developing our seed-to-sale intellectual property (IP) in Canada and are now moving it into different countries like Australia, Colombia, and are working on going into both Israel and Holland as well.
INN: As the company’s founder, how has your vision for MYM shifted since the company’s inception?
EF: When we started MYM, the initial intent for the company was obtain our ACMPR production license and to develop a global, fully integrated brand with various IPs. We started out by taking those steps and we have since created numerous product lines. We are also working with various extraction companies to find the best use for cannabis by-products and delivery systems.
As we expand into different countries, we have done so with the goal of creating impactful footprints in each jurisdiction, particularly through economic growth, job development and the opportunity for governments to create further taxable income. We are also focused on educating the people we work with and around.
When we entered Weedon, Quebec, there was a lack of understanding regarding the cannabis plant. To help address that, we have worked on creating a syndicate of doctors from the University of Sherbrooke and are also talking to a group of doctors at the University of British Columbia. We have also replicated this in Colombia and Australia and are talking to a number of doctors there, inclusively at Southern Cross University.
With this switch in vision, we are stepping beyond just production and manufacturing and are moving towards doing more impactful things.
INN: Please tell our investors about MYM’s upcoming facility in Weedon, Quebec. Besides production and manufacturing, what are the goals for the facility?
Fear and Debt Push Gold to New Heights in 2020. What's coming in 2021?
Precious Metals Outlook INNvestor Report Download today!
EF: Besides manufacturing and production, the goal at Weedon was initially to help create job security within the municipality. In discussions with the mayor, we were informed that the current industries in Weedon were struggling to stay open and to retain employees. This meant that the city was losing its workforce. What we did was to create an opportunity to increase employment in Weedon while also increasing education, resource and development, tourism by building an ecosystem.
INN: What is next for MYM and how does that fit into the company’s long-term plans?
EF: We are going to continue our global expansion while also interacting with universities and researchers in each region we work in, and creating a global syndicate of doctors for research and development clinical studies. Through these studies, we want to uncover how the plant can continue to be utilized for human and animal consumption, and also help inform the communities we work within so that they can make informed policy decisions. We feel that it is important for the public to be educated on the health benefits associated to cannabis, and also on the economic growth the industry can provide.
INN: As MYM advances the build of its facilities in Quebec, what are your expectations for the Canadian cannabis market with legalization on the horizon?
EF: With legalization, Canada will become a global leader in the best practises and quality production, while also leading the way in research and development and clinical studies used to educate the public.
Legalization also offers the opportunity to create a vast workforce that will cover various aspects of the plant and its products. This could include jobs in developing packaging to accessories to textiles.
If the market does become oversaturated, we at MYM have positioned ourselves to be a leader in the exportation of medical cannabis by extending our footprint across a number of different countries and creating relationships with those who have an impactful position within global exportation.
CEO interviews are part of investor education campaigns for clients advertising on the Investing News Network. Important news is contextualized by CEOs, and the resulting interviews are disseminated to the Investing News Network audience because they have value to market watchers.
The Investing News Network interviews a CEO for an understanding of their perspective on the company, the investment potential of the company and market news related to the company. The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).